Last updated on February 2018

A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients

Brief description of study

Acute myeloid leukemia (AML) is a disease with a poor prognosis including a 5-year overall survival (OS) of app. 20% for the entire population. In particular, the outcome of elderly patients with AML is dismal and the majority of patients die within the first year after diagnosis. This is also because treatment options for elderly patients with AML significantly differ from patients of younger age. In fact, comorbid conditions are common among the elderly such as heart disease, renal insufficiency and vascular disease thus influencing the ability to withstand intensive therapy. Elderly patients are also more likely than younger patients to develop severe, life threatening infections during the course of treatment. In addition to infectious complications, hemorrhages due to severe thrombocytopenia are responsible for morbidity and mortality in a considerable amount of patients. Compared with younger AML patients, elderly individuals with AML display a higher incidence of poor-prognosis karyotypes, of a preceding myelodysplastic syndrome (MDS), and greater expression of proteins involved in intrinsic resistance to chemotherapeutic agents. As a result conventional anthracycline based chemotherapy is only infrequently used in patients above the age of 65 years. Based on a recent randomized trial (Kantarjian et al. 2012) low-intensity epigenetic therapy with decitabine (DAC) has become the first-line standard of care in most European countries including Germany. Nevertheless, even with this treatment the 1-year OS is approximately 30 % only. Furthermore, severe thrombocytopenia is a main side effect of this therapy and can prevent adequate continuation of treatment being crucially for treatment success. Supportive care with platelet transfusions is effective primarily only over short periods and often requires hospitalization and therefore lowers the quality of life of these patients in their palliative situation. Therefore, patients could benefit from an approach aiming at an increase of platelet counts through combined use of DAC with an oral thrombopoietin receptor agonist like eltrombopag (EPAG). This could allow for a better adherence to DAC therapy by preventing dose delays due to prolonged thrombocytopenia. Additionally, the potential antileukemic effect of EPAG could also be beneficial for these AML patients.

Detailed Study Description

The DELTA-trial is designed as a two-arm, double-blind, multicenter randomized-controlled phase- II study of EPAG or placebo in combination with standard-dose DAC treatment as concomitant medication in subjects at least 65 years of age with AML not eligible for intensive chemotherapy and planned therapy with Decitabine (DAC). Patients will be randomized 1:1 into the experimental study arm and the control study arm. EPAG 200 mg (100 mg for East Asian patients) once daily has been selected as the starting dose for this study because this regimen has been investigated to be safe and potentially effective in increasing platelet counts in patients with AML. Concomitant medication with DAC will be according to the european label and the summary of product characteristics. There will be a dose adjustment of EPAG depending on the platelet counts obtained on day 1 of a planned DAC cycle.

Concomitant medication will be Decitabine (DAC) 20 mg/m2 i.v. over 30 minutes on days 1-5 of each cycle. One cycle lasts 28 days. Patients will receive medication as long as they benefit from treatment and in the absence of relevant adverse events indicating a treatment discontinuation; but for a maximum of 12 cycles. During Follow Up (up to 4 years) patient survival and first treatment change will be observed.

Clinical Study Identifier: NCT02446145

Contact Investigators or Research Sites near you

Start Over

Martina Crysandt, MD

Uniklinik RWTH Aachen
Aachen, Germany
  Connect »

Claudia Baldus, Prof.

Charite Campus Benjamin Franklin
Berlin, Germany
  Connect »

Mathias Hänel, MD

Klinikum Chemnitz GmbH
Chemnitz, Germany
  Connect »

Uwe Platzbecker, Prof.

Universit tsklinikum Dresden
Dresden, Germany
  Connect »

Richard Noppeney, MD

Universit tsklinikum Essen
Essen, Germany
  Connect »

Petra Tschanter, MD

Universit tsklinikum Halle (Saale)
Halle, Germany
  Connect »

Heinz A Dürk, MD

St. Marien-Hospital Hamm
Hamm, Germany
  Connect »

Hartmut Linde, MD

Medizinisches Versorgungszentrum f r Blut- und Krebserkrankungen
Potsdam, Germany
  Connect »

Andreas Lück, MD

Wissenschaftskontor Nord GmbH & Co KG
Rostock, Germany
  Connect »

Stefani Parmentier, MD

Rems-Murr-Klinikum Winnenden
Winnenden, Germany
  Connect »

Aristoteles Giagounidis, MD

Marienhospital D sseldorf GmbH
Düsseldorf, Germany
  Connect »

Katharina Götze, MD

Klinikum rechts der Isar der TU M nchen
München, Germany
  Connect »

Kerstin Schäfer-Eckart, MD

Klinikum N rnberg-Nord
Nürnberg, Germany
  Connect »

Thomas Geer, MD

Diakonie-Klinikum Schw bisch Hall gGmbH
Schwäbisch Hall, Germany
  Connect »

Volker Kunzmann, Prof.

Universit tsklinikum W rzburg
Würzburg, Germany
  Connect »